clonoSEQ for minimal residual disease assessment in multiple myeloma, acute lymphoblastic leukaemia and chronic lymphocytic leukaemia

  • Medtech innovation briefing
  • MIB278
  • Published: 
Download (PDF)

Regulatory information

clonoSEQ is a CE-marked class III medical device.

The following manufacturer field safety notices or medical device alerts for this technology have been identified and are consistent with all diagnostics:

  • false positive results

  • false negative results.